Registering new drugs for low-income countries: The African challenge

PLoS Medicine

Volumn 8, Issue 2, 2011, Pages

  Moran, Mary ^a   Strub Wourgaft, Nathalie ^b   Guzman, Javier ^a   Boulet, Pascale ^b   Wu, Lindsey ^a   Pecoul, Bernard ^b  

^a Policy Cures   (Australia)

^b Drugs for Neglected Diseases Initiative DNDi   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMODIAQUINE PLUS ARTESUNATE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTEROLANE; ARTESUNATE PLUS MEFLOQUINE; AZITHROMYCIN PLUS CHLOROQUINE; DIHYDROARTEMISININ PLUS PIPERAQUINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; FEXINIDAZOLE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; MOXIFLOXACIN; NEW DRUG; PAROMOMYCIN; RIFAPENTINE; ROTAVIRUS VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; DRUG APPROVAL; DRUG EFFICACY; DRUG LEGISLATION; DRUG QUALITY; DRUG SAFETY; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; GOVERNMENT REGULATION; HIGH RISK BEHAVIOR; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; REGISTRATION; ROTAVIRUS INFECTION; SOCIOECONOMICS; TUBERCULOSIS; WORLD HEALTH ORGANIZATION; DEVELOPING COUNTRY; LEGAL ASPECT; NEGLECTED DISEASE; ORGANIZATION AND MANAGEMENT; POVERTY; REGISTER;

AFRICA; DEVELOPING COUNTRIES; DRUG APPROVAL; GOVERNMENT REGULATION; HUMANS; NEGLECTED DISEASES; POVERTY; REGISTRIES;

EID: 79952258411     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000411     Document Type: Article

References (23)

1. Belgharbi L, (2007) Vaccine regulatory issues in African countries: building & sustaining national capacity. EDCTP consultative meeting; 11 June 2007; Geneva, Switzerland. Available: http://www.edctp.org/fileadmin/documents/Regulatory_meeting_Lahouari_Belgharbi.pdf. Accessed 4 January 2011.
2. World Health Organization (2006) Comite Regional de l'Afrique. Cinquante-sixieme session, Addis-Abeba, Ethiopie, 2 aout-1er septembre 2006. Autorites de reglementation pharmaceutique: situation actuelle et perspectives: Report du Directeur regional. Available: http://afrolib.afro.who.int/RC/RC%2056/Doc_Fr/AFR%20RC56%2011%20AUTORITES%20%20REGLEMENT%20PHARMACEUTIQUE.pdf. Accessed 23 September 2010.
3. World Health Organization (2010) Regulatory harmonization: updating medicines regulatory systems in sub-Saharan African countries. WHO Drug Information 24 (1): 6-20 Available: http://whqlibdoc.who.int/druginfo/24_1_2010.pdf. Accessed 4 January 2011.
4. Moran M, Guzman J, McDonald A, Wu L, Omune B, (2010) Registering new drugs: the African context. London: Health Policy Division, The George Institute for International Health. Available: http://www.dndi.org/images/stories/advocacy/regulatory-report_george-institute-dndi_jan2010.pdf. Accessed 4 January 2011.
5. US Food and Drug Administration (2010) Orange book: approved drug products with therapeutic equivalence evaluations. Available: http://www.accessdata.fda.gov/scripts/cder/ob/docs/obdetail.cfm?Appl_No=021752&TABLE1=OB_Rx. Accessed 4 January 2011.
6. US Food and Drug Administration (2010) President's Emergency Plan for AIDS Relief: Approved and tentatively approves antiretrovirals in association with the President's Emergency Plan. Available: http://www.fda.gov/internationalprograms/fdabeyondourbordersforeignoffices/asiaandafrica/ucm119231.htm. Accessed 4 January 2011.
7. Cipla (2007) Once-daily dosage lamivudine another ARV first for Cipla Medpro. Available: http://www.ciplamedpro.co.za/news.php?nid=26. Accessed 4 January 2011.
8. Act with ASMQ (2008) A worldwide public partnership makes available a new, once-a-day fixed-dose combination against malaria. Available: http://www.actwithasmq.org/index2.php?inter=0&&hight=0. Accessed 4 January 2011.
9. Act with ASAQ (2010) ASAQ: hope for malaria. Available: http://www.actwithasaq.org/en/asaq1.htm. Accessed 4 January 2011.
10. Nwaka S, Ilunga TB, Da Silva JS, Rial Verde E, Hackley D, et al. (2010) Developing ANDI: a novel approach to health product R&D in Africa. PLoS Med 7 (6): e1000293 doi:10.1371/journal.pmed.1000293.
11. Institute for One World Health (2010) Next steps. Available: http://www.oneworldhealth.org/next_steps. Accessed 4 January 2011.
12. Novartis (2008) Novartis receives FDA priority review for Coartem®, potentially the first artemisinin-based combination treatment (ACT) for malaria in the US [press release]. Basel Novartis Available: http://hugin.info/134323/R/1251164/271951.pdf. Accessed 6 January 2011.
13. World Health Organization (2010) HA210 World Health Organization public assessment report. Available: http://apps.who.int/prequal/WHOPAR/WHOPARPRODUCTS/TriomunePart7v10.pdf. Accessed 4 January 2011.
14. US Food and Drug Administration (2009) FDA Approves Coartem tablets to treat malaria. Available: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149559.htm. Accessed 4 January 2011.
15. World Health Organization (2010) WHO list of prequalified medicinal products. Available: http://apps.who.int/prequal/. Accessed 4 January 2011.
16. Institute for One World Health (2009) Visceral leishmaniasis. Available: http://www.oneworldhealth.org/leishmaniasis. Accessed 4 January 2011.
17. World Health Organization (2008) HA343 World Health Organization public assessment report. Available: http://apps.who.int/prequal/WHOPAR/WHOPARPRODUCTS/HA343Part7v2.pdf. Accessed 4 January 2011.
18. European Medicines Agency (2005) Background information on the procedure. Available: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_steps_taken_before_authorisation/human/000594/WC500043717.pdf. Accessed 16 March 2010.
19. Gilead (2010) Gilead international access operations. Available: http://www.gilead.com/pdf/GAP_Registration_Status.pdf. Accessed 4 January 2011.
20. Medicines for Malaria Venture (2010) MMV Interactive Science Portfolio, Q4 2010. Geneva: Medicines for Malaria Venture. Available: http://www.mmv.org/research-development/science-portfolio. Accessed 6 January 2011.
21. Global Alliance for TB Drug Development (2011) TB Alliance portfolio March 2010. New York: Global Alliance for TB Drug Development. http://www.tballiance.org/new/portfolio/html-portfolio.php. Accessed 6 January 2011.
22. Wells T (2009) Building a robust portfolio of new medicines. Drug Discovery World. Available: http://www.ddw-online.com/therapeutics/258406/building_a_robust_portfolio_of_new_medicines.html. Accessed 6 January 2011.
23. Drugs for Neglected Disease Initiative (2010) Fexinidazole (HAT). Available: http://www.dndi.org/portfolio/fexinidazole.html. Accessed 6 January 2011.